Candel Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Needham, MA
CADL chart
What traders are saying about $CADL
Latest postsCandel Therapeutics, Inc. news
- Candel Therapeutics to Present at November Investor Conferences
Yahoo Finance ·
- Candel Therapeutics, Inc. Estimates – NASDAQ:CADL
TradingView ·
- Candel Therapeutics Appoints Maria Ostrovsky General Counsel Ahead of Planned FDA Submission
citybiz ·
- Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
Yahoo Finance ·
- Candel Therapeutics initiated with a Buy at Jefferies
TipRanks ·
- Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data
Investing.com ·
- Candel Therapeutics to Present at the SITC 2026 Annual Meeting
Yahoo Finance ·
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
Yahoo Finance ·
- CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’
stocktwits.com ·
- Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
Yahoo Finance ·
- Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
Yahoo Finance ·
Candel Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | $125,000 |
| Net income | -$38.2M | -$55.2M | -$37.9M | -$18.8M |
| Diluted EPS | $-0.72 | $-1.74 | $-1.31 | $-0.65 |
| Total assets (year end) | $125.2M | $106.9M | $41.2M | $77.7M |
| Cash and equivalents (year end) | $119.7M | $102.7M | $35.4M | $70.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Candel Therapeutics, Inc.
- Ticker
- CADL (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Needham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1841387
Frequently asked questions
What exchange is Candel Therapeutics, Inc. listed on?
Candel Therapeutics, Inc. trades on the Nasdaq under the ticker symbol CADL.
What industry is Candel Therapeutics, Inc. in?
Candel Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Candel Therapeutics, Inc. headquartered?
Candel Therapeutics, Inc.'s business address on file with the SEC is in Needham, MA.
When does Candel Therapeutics, Inc.'s fiscal year end?
Candel Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Candel Therapeutics, Inc. report?
Candel Therapeutics, Inc. reported $125,000 in revenue for calendar year 2022, according to its SEC filings.